BLT Share Price

Open 0.15 Change Price %
High 0.15 1 Day -0.01 -6.67
Low 0.14 1 Week -0.01 -6.67
Close 0.14 1 Month -0.05 -26.32
Volume 135555 1 Year 0.04 40.00
52 Week High 0.28
52 Week Low 0.08
BLT Important Levels
Resistance 2 0.15
Resistance 1 0.15
Pivot 0.14
Support 1 0.13
Support 2 0.13
ASX Australia Most Active Stocks
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
FMG 4.85 -4.53%
FMG 4.85 -4.53%
FXJ 1.26 0.80%
AGO 0.02 0.00%
AGO 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
AZS 0.02 100.00%
AZS 0.02 100.00%
LTR 0.02 100.00%
LTR 0.02 100.00%
ESI 0.02 100.00%
ESI 0.02 100.00%
ESI 0.02 100.00%
ESI 0.02 100.00%
ESI 0.02 100.00%
More..
ASX Australia Top Losers Stocks
VXR 0.00 -100.00%
GMR 0.00 -100.00%
GMR 0.00 -100.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GBG 0.01 -50.00%
GBG 0.01 -50.00%
More..

Benitec Biopharma Ltd (ASX: BLT)

BLT Technical Analysis 2
As on 26th May 2017 BLT Share Price closed @ 0.14 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.13 & Strong Sell for SHORT-TERM with Stoploss of 0.17 we also expect STOCK to react on Following IMPORTANT LEVELS.
BLT Target for May
1st Target up-side 0.24
2nd Target up-side 0.28
3rd Target up-side 0.32
1st Target down-side 0.12
2nd Target down-side 0.08
3rd Target down-side 0.04
BLT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.benitec.com
BLT Address
BLT
Level 16
356 Collins Street
Melbourne, VIC 3000
Australia
Phone: 61 2 9555 6986
Fax: 61 3 8678 1342
BLT Latest News
Interactive Technical Analysis Chart Benitec Biopharma Ltd ( BLT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Benitec Biopharma Ltd
BLT Business Profile
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company’s ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Nervarna to treat chronic cancer-associated pain; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington’s disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.